Evaluating the Efficacy and Safety of QL0911 in Chemotherapy- Induced Thrombocytopenia

Exclusion Criteria

• •Suffering from other hematopoietic diseases except lymphoma, including leukemia, primary immune thrombocytopenia, myeloproliferative diseases, multiple myeloma and myelodysplastic syndrome;
• •Thrombocytopenia caused by non-tumor chemotherapy drugs occurred within 6 months before screening, including but not limited to EDTA-dependent pseudothrombocytopenia, hypersplenism, infection and bleeding;
• •Bone marrow invasion or bone marrow metastasis occurs;
• •Being receiving radiotherapy or having received abdominal or pelvic radiotherapy within 3 months;
• •There have been any arterial or venous thrombosis events within 6 months before screening;
• •Screening patients with severe cardiovascular disease (NYHA cardiac function score III-IV) and arrhythmia that increases the risk of thrombosis, such as atrial fibrillation, after coronary stent implantation, angioplasty and coronary artery bypass grafting;
• •Clinical manifestations of severe bleeding (such as gastrointestinal bleeding, etc.) within 2 weeks before screening;
• •Received platelet transfusion within 2 days before randomization;
• •Patients have been treated with thrombopoietin receptor agonists (such as romistine and itrapoppa) or human recombinant thrombopoietin (rhTPO) or rhIL-11 within 4 weeks before the first administration;
• •Anticoagulant drugs such as heparin, warfarin and aspirin have been used within 7 days before the first administration;
• •Received bone marrow transplantation or stem cell infusion within one year before screening;
• •Patients with chronic hepatitis B or hepatitis C in active period, and patients with positive antibodies to human immunodeficiency virus;
• •The absolute value of neutrophils in the screening period is less than 1.5× 109/L, and hemoglobin is less than 90g/L;
• •The total bilirubin in the screening period is more than 3 times the upper limit of the normal range; Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were higher than the upper limit of normal range by 3 times. For patients with liver metastasis, alanine aminotransferase (ALT) and aspartate aminotransferase (AST)≥ 5 times the upper limit of the normal range;
• •Blood creatinine concentration ≥1.5ULN or EGFR ≤ 60 ml/min;
• •patients with severe drug allergic reaction;
• •Patients who have used any research drugs (excluding vitamins and minerals) within 3 months before the first administration;
• •Patients who plan pregnancy, pregnancy or lactation;
• •The researcher judges the patients who are not suitable for this experiment.